Curbstone Financial Management »

Halozyme Therapeutics shares owned by Curbstone Financial Management

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Curbstone Financial Management from 13F filings

Historical chart of Curbstone Financial Management investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Curbstone Financial Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Curbstone Financial Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $472k 8.2k 57.24
2024-06-30 $431k 8.2k 52.36

More positions owned by Curbstone Financial Management

SPDR Inv't Grade Floating Rate Bdfund (FLRN)
SPDR S&P Midcap 400 Etf (MDY)
Apple (AAPL)
Vanguard ST Corp Bond ETF Bdfund (VCSH)
Vanguard S&P 500 ETF Etf (VOO)
Schwab Large Cap Growth ETF Etf (SCHG)
Schwab US Mid Cap ETF Etf (SCHM)
Schwab International Equity ET Etf (SCHF)
Schwab US Dividend Equity Etf (SCHD)
Microsoft Corporation (MSFT)
Schwab US Small Cap ETF Etf (SCHA)
Vanguard Intermediate Corp Bon Bdfund (VCIT)
Amazon (AMZN)
Alphabet Inc Class C cs (GOOG)
Schwab US Broad Market ETF Etf (SCHB)

View all positions for Curbstone Financial Management

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Snyder Capital Management
Alliancebernstein
Artisan Partners Limited Partnership
Geode Capital Management
Macquarie Group
Jpmorgan Chase & Co
Congress Asset Management
Bank of America Corporation
Arrowpoint Asset Management
Goldman Sachs Group
Handelsbanken Fonder AB
Invesco

View all funds holding Halozyme Therapeutics